PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies) - Global Forecast to 2021

  • ID: 3949933
  • Report
  • Region: Global
  • Markets and Markets
1 of 5
The Global PEGylated Proteins Market is Expected to Reach USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016 at a CAGR of 10.5% between 2016 and 2021

FEATURED COMPANIES

  • Biomatrik, Inc.
  • Celares GmbH
  • Creative Pegworks
  • Iris Biotech GmbH
  • Jenkem Technology
  • Laysan Bio, Inc.
  • MORE

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, and increase in adoption of protein based drugs over non-protein based drugs. In addition, rising opportunities in emerging markets, and top-selling biologics drugs going off-patent in the near future provides a growing opportunity to this market.

This report segments the global PEGylated proteins market by product, protein type, application and end-user. By product, the market includes consumables and services. Based on protein type, the market is segmented into colony stimulating factors, interferons, erythropoietin, mAbs, and recombinant factor VIII. The colony stimulating factors segment will hold the largest share of the PEGylated proteins type market in 2016.

The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the PEGylated proteins market in 2016. Asia is expected to register the fastest growth in the forecast period.

Research Coverage:

This report studies the PEGylated proteins market based on product, protein type, application, and end-user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation: Product portfolios of the top players in the PEGylated proteins market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the insights on upcoming technologies market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the PEGylated proteins market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various PEGylated proteins across geographies
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the PEGylated proteins market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biomatrik, Inc.
  • Celares GmbH
  • Creative Pegworks
  • Iris Biotech GmbH
  • Jenkem Technology
  • Laysan Bio, Inc.
  • MORE
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Report
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.3.3 Assumptions for the Study

3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights
4.1 Global PEGylated Proteins Market Overiew
4.2 Market: By End-User & Region
4.3 Market: Geographic Snapshot
4.4 Life Cycle Analysis, By Region (2016)

5 Industry Insights
5.1 Introduction
5.2 Market Indicators
5.2.1 Increasing R&D Spending in Pharmaceutical and Biotechnology Sector
5.3 Strategic Benchmarking
5.3.1 Agreement & Collaboration
5.4 Porter’s Five Forces Analysis
5.4.1 Threat From New Entrants
5.4.2 Threat From Substitutes
5.4.3 Bargaining Power of Suppliers
5.4.4 Bargaining Power of Buyers
5.4.5 Intensity of Competitive Rivalry
5.5 Regulatory Scenario
5.6 Pipeline Analysis

6 Market Overview
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.1.1 Increase in R&D Spending
6.2.1.2 Growth in Biologics Sector to Propel the PEGylated Proteins Market
6.2.1.3 Increase in Adoption of Protein-Based Drugs Over Non-Protein-Based Drugs
6.2.1.4 Increasing Protein’s Stability and Circulating Half-Life
6.2.1.5 High Prevalence Rate of Lifestyle Diseases
6.2.2 Restraints
6.2.2.1 Drug Failure and Recalls Hinders Market Growth
6.2.3 Opportunities
6.2.3.1 Rising Opportunities in Emerging Markets
6.2.3.2 Top-Selling Biologics Drugs Going Off–Patent in the Near Future
6.2.4 Challenge
6.2.4.1 Increasing Market Consolidation Increases Entry  Barriers and Restraints Market Growth

7 PEGylated Proteins Market, By Product
7.1 Introduction
7.2 Consumbales
7.2.1 Pegylation Kits
7.2.2 Pegylation Reagents
7.2.2.1 Monofunctional Linear Pegs
7.2.2.2 Bifunctional Pegs
7.2.2.3 Multi-Arm Pegs
7.2.2.4 Branched Pegs
7.2.2.5 Other Pegylation Reagents
7.3 Services
7.3.1 Development of PEGylated Biosimilars
7.3.2 Process Development of Peg-Drug Conjugate Manufacturing
7.3.3 Pilot Production of Peg Drug Conjugate
7.3.4 Development of Analytical Methods
7.3.5 Pegylation Feasibility Studies

8 PEGylated Proteins Market, By Protein Type
8.1 Key Findings
8.2 Introduction
8.3 Colongy Stimulating Factors
8.4 Interferons
8.5 Erythropoietin (EPO)
8.6 Recombinant Factor Viii
8.7 Monoclonal Antibodies
8.8 Other Protein Type

9 PEGylated Proteins Market, By Application
9.1 Key Findings
9.2 Introduction
9.3 Cancer Treatment
9.4 HEPAtitis
9.5 Chronic Kidney Disease
9.6 Hemophilia
9.7 Multiple Sclerosis
9.8 Gastrointestinal Disorder
9.9 Other Application

10 End-User Market, By End-User
10.1 Key Findings
10.2 Introduction
10.3 Pharmaceutical & Biotechnology Companies
10.4 Contract Research Organization
10.5 Academic Research Institutes

11 PEGylated Proteins Market, By Region
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.4 Asia
11.5 Rest of the World

12 Competitive Landscape
12.1 Introduction
12.2 Strategic Analysis
12.3 Market Share Analysis
12.4 Competitive Situation and Trends
12.4.1 Agreements & Collaboration
12.4.2 New Product Launches and Product Showcase
12.4.3 Acquisitions
12.4.4 Product Upgradation

13 Company Profiles
13.1 Introduction
13.2 Merck Millipore
13.2.1 Business Overview
13.2.2 Products Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.2.4.1 Financial Analysis
13.2.4.2 Strategic Analysis
13.3 Thermo Fisher Scientific Inc.
13.3.1 Business Overview
13.3.2 Products Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.3.4.1 Financial Analysis
13.3.4.2 Strategic Analysis
13.4 NOF American Corporation (A Subsidiary of NOF Corporation)
13.4.1 Business Overview
13.4.2 Products Offered
13.4.3 Recent Developments
13.4.4 MnM View
13.4.4.1 Financial Analysis
13.4.4.2 Strategic Analysis
13.5 Jenkem Technology
13.5.1 Business Overview
13.5.2 Products Offered
13.5.3 Recent Developments
13.5.3.1 Strategic Analysis
13.6 Creative Pegworks
13.6.1 Business Overview
13.6.2 Products Offered
13.6.3 Recent Developments
13.7 Celares GmbH
13.7.1 Business Overview
13.7.2 Products Offered
13.7.3 Recent Developments
13.8 Quanta Biodesign, Ltd
13.8.1 Business Overview
13.8.2 Products Offered
13.8.3 Recent Developments
13.9 Biomatrik, Inc.
13.9.1 Business Overview
13.9.2 Products Offered
13.9.3 Recent Developments
13.10 Iris Biotech GmbH
13.10.1 Business Overview
13.10.2 Products Offered
13.10.3 Recent Developments
13.11 Laysan Bio, Inc.
13.11.1 Business Overview
13.11.2 Products Offered
13.11.3 Recent Developments

14 Appendix
14.1 Insights of Industry Experts
14.2 Discussion Guide

List of Tables

Table 1 PEGylated Proteins Market Summary
Table 2 Market Size, By Product, 2014–2021 (USD Million)
Table 3 Market Size for Consumables, By Type, 2014–2021 (USD Million)
Table 4 Market Size for Consumables, By Region, 2014–2021 (USD Million)
Table 5 North America: Market Size for Consumables, By Region, 2014–2021 (USD Million)
Table 6 Market Size for Pegylation Kits, By Region, 2014–2021 (USD Million)
Table 7 North America: Market Size for Pegylation Kits, By Region, 2014–2021 (USD Million)
Table 8 Market Size for Pegylation Reagents, By Region, 2014–2021 (USD Million)
Table 9 North America: Market Size for Pegylation Reagents, By Region, 2014–2021 (USD Million)
Table 10 Market Size for Services, By Region, 2014–2021 (USD Million)
Table 11 North America: Market Size for Services, By Region, 2014–2021 (USD Million)
Table 12 Market Size for Development of PEGylated Biosimilars, By Region, 2014–2021 (USD Million)
Table 13 North America: Market Size for Development of PEGylated Biosimilars, By Region, 2014–2021 (USD Million)
Table 14 Market Size for Process Development of Peg-Conjugate Manufactuirng , By Region, 2014–2021 (USD Million)
Table 15 North America: Market Size for Process Development of Peg-Conjugate Manufactuirng, By Region, 2014–2021 (USD Million)
Table 16 Market Size for Pilot Production of Peg Drug Conjugate, By Region, 2014–2021 (USD Million)
Table 17 North America: Market Size for Pilot Production of Peg Drug Conjugate, By Region, 2014–2021 (USD Million)
Table 18 Market Size for Development of Analytical Methods, By Region, 2014–2021 (USD Million)
Table 19 North America: Market Size for Development of Analytical Methods, By Region, 2014–2021 (USD Million)
Table 20 Market Size for PEGylation Feasibility Studies , By Region, 2014–2021 (USD Million)
Table 21 North America: Market Size for PEGylation Feasibility Studies, By Region, 2014–2021 (USD Million)
Table 22 Colony Stimulating Factors Market Size, By Protein Type, 2014–2021 (USD Million)
Table 23 Market Size for Colony Stimulating Factors, By Region, 2014–2021 (USD Million)
Table 24 North America: Market Size for Colony Stimulating Factors, By Region, 2014–2021 (USD Million)
Table 25 Market Size for Interferon, By Region, 2014–2021 (USD Million)
Table 26 North America: Market Size for Interferon, By Region, 2014–2021 (USD Million)
Table 27 Market Size for Erythropoietin, By Region, 2014–2021 (USD Million)
Table 28 North America: Market Size for Erythropoietin, By Region, 2014–2021 (USD Million)
Table 29 Market Size for Recombinant Factor Viii, By Region, 2014–2021 (USD Million)
Table 30 North America: Market Size for Recombinant Factor Viii, By Region, 2014–2021 (USD Million)
Table 31 Market Size for Monoclonal Antibodies, By Region, 2014–2021 (USD Million)
Table 32 North America: Market Size for Monoclonal Antibodies, By Region, 2014–2021 (USD Million)
Table 33 Market Size for Other Protein Type, By Region, 2014–2021 (USD Million)
Table 34 North America: PEPylated Proteins Market Size for Other Protein Type, By Region, 2014–2021 (USD Million)
Table 35 Cancer Treatment Market Size, By Application, 2014–2021 (USD Million)
Table 36 Market Size for Cancer Treatment, By Region, 2014–2021 (USD Million)
Table 37 North America: Market Size for Cancer Treatment, By Region, 2014–2021 (USD Million)
Table 38 Market Size for Hepatitis, By Region, 2014–2021 (USD Million)
Table 39 North America: Market Size for Hepatitis, By Region, 2014–2021 (USD Million)
Table 40 Market Size for Chronic Kidney Disease, By Region, 2014–2021 (USD Million)
Table 41 North America: Market Size for Chronic Kidney Disease, By Region, 2014–2021 (USD Million)
Table 42 Market Size for Hemophilia, By Region, 2014–2021 (USD Million)
Table 43 North America: Market Size for Hemophilia, By Region, 2014–2021 (USD Million)
Table 44 Market Size for Multiple Sclerosis, By Region, 2014–2021 (USD Million)
Table 45 North America: Market Size for Multiple Sclerosis, By Region, 2014–2021 (USD Million)
Table 46 Market Size for Gastrointestinal Disorder, By Region, 2014–2021 (USD Million)
Table 47 North America: Market Size for Gastrointestinal Disorder , By Region, 2014–2021 (USD Million)
Table 48 Market Size for Other Applications, By Region, 2014–2021 (USD Million)
Table 49 North America: Market Size for Other Application, By Region, 2014–2021 (USD Million)
Table 50 Market Size, By End-User, 2014–2021 (USD Million)
Table 51 Market Size for Pharmaceutical & Biotechnology Companies Segment, By Region, 2014–2021 (USD Million)
Table 52 North America: Market Size for Pharmaceutical & Biotechnology Companies , By Region, 2014–2021 (USD Million)
Table 53 Market Size for Contract Research Organizations Segment, By Region, 2014–2021 (USD Million)
Table 54 North America: Market Size for Contract Research Organizations, By Region, 2014–2021 (USD Million)
Table 55 PEGylated Proteins Market Size for Academic Research Institutes, By Region, 2014–2021 (USD Million)
Table 56 North America: PEGylated Proteins Market Size for Academic Research Institutes, By Region, 2014–2021 (USD Million)
Table 57 PEGylated Proteins Market Size, By Region, 2014–2021 (USD Million)
Table 58 North America: PEGylated Proteins Market Size, By Region, 2014–2021 (USD Million)
Table 59 North America: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 60 North America: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 61 North America: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 62 North America: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 63 U.S: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 64 U.S: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 65 U.S: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 66 U.S: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 67 Canada: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 68 Canada: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 69 Canada: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 70 Canada: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 71 Europe: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 72 Europe: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 73 Europe: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 74 Europe: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 75 Asia: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 76 Asia: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 77 Asia: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 78 Asia: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 79 RoW: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 80 RoW: PEGylated Proteins Market Size, By Protein Type, 2014–2021 (USD Million)
Table 81 RoW: PEGylated Proteins Market Size, By Application, 2014–2021 (USD Million)
Table 82 RoW: PEGylated Proteins Market Size, By End User, 2014–2021 (USD Million)
Table 83 Market Developments Between January 2013 and May 2016
Table 84 Agreements & Collaborations, 2013–2016
Table 85 New Product Launches and Product Showcase, 2013–2016
Table 86 Acquisitions, 2013–2016
Table 87 Product Upgradation, 2013–2016

List of Figures

Figure 1 PEGylated Proteins Market
Figure 2 Research Design
Figure 3 PEGylated Proteins Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 PEGylated Proteins Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 PEGylated Proteins Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 PEGylated Proteins Market Size, By Protein Type, 2016 vs 2021 (USD Million)
Figure 9 PEGylated Proteins Market Size, By Application, 2016 vs 2021 (USD Million)
Figure 10 PEGylated Proteins Market Size, By End-User, 2016 vs 2021 (USD Million)
Figure 11 PEGylated Proteins Market, By Region, 2016 (USD Million)
Figure 12 PEGylated Proteins Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 13 Increase in R&D Spending to Drive Market Growth
Figure 14 Pharmaceutical & Biotechnology Companies to Command the Largest Market Share in 2016
Figure 15 Asia to Register Highest Growth During the Forecast Period
Figure 16 Asia Holds Lucrative Growth Opportunities in the PEGylated Proteins Market
Figure 17 Increasing R&D Investments in Pharma Industry Boosting the Growth of the PEGylated Proteins Market
Figure 18 Market Leaders Adopted the Inorganic Growth Strategy of Agreement & Collaboration
Figure 19 Porter’s Five Forces Analysis (2016)
Figure 20 Increase in R&D Spending Will Drive the PEGylated Proteins Market
Figure 21 Patent Application By Region, 2013
Figure 22 Consumables Segment Commands the Largest Share of the PEGylated Proteins Market in 2016
Figure 23 Pegylation Kits Segment Commands the Largest Share of the Consumables Market in 2016
Figure 24 Pegylation Reagents, By Type
Figure 25 Development of PEGylated Biosimilars Segment Commands the Largest Share of the Services Market in 2016
Figure 26 Colony Stimulating Factors to Command the Largest Share of the PEGylated Proteins Type Market in 2016
Figure 27 Cancer Treatment to Command the Largest Share of the PEGylated Protein Application Market in 2016
Figure 28 Pharmaceutical & Biotechnology Companies to Command the Largest Share of the PEGylated Proteins End-User Market in 2016
Figure 29 PEGylated Proteins Market Segmentation, By Region: Market Size and Growth Rate, 2016-2021
Figure 30 Asian Market for PEGylated Proteins Expected to Grow at the Highest Rate (2016 to 2021)
Figure 31 North America: PEGylated Proteins Market Snapshot
Figure 32 Canada to Grow at the Highest Rate in North America
Figure 33 Consumables, the Largest Product Segment in North America
Figure 34 Colony Stimulating Factors Protein Type Segment Dominates the North American PEGylated Proteins Market
Figure 35 Cancer Treatment, the Largest Application Segment in North America
Figure 36 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the North American Market
Figure 37 Consumables, the Largest Product Segment in U.S
Figure 38 Colony Stimulating Factors Protein Type Segment Dominates the U.S PEGylated Proteins Market
Figure 39 Cancer Treatment, the Largest Application Segment in U.S
Figure 40 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the U.S Market
Figure 41 Consumables, the Largest Product Segment in Canada
Figure 42 Colony Stimulating Factors Protein Type Segment Dominates the Canada PEGylated Proteins Market
Figure 43 Cancer Treatment, the Largest Application Segment in Canada
Figure 44 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the Canada Market
Figure 45 Europe: PEGylated Proteins Market Snapshot (2016)
Figure 46 Consumables, the Largest Product Segment in Europe
Figure 47 Colony Stimulating Factors Type Segment Dominates the European PEGylated Proteins Market
Figure 48 Cancer Treatment, the Largest Application Segment in Europe
Figure 49 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the European Market
Figure 50 Asia: PEGylated Proteins Market Snapshot
Figure 51 Consumables, the Largest Product Segment in Asia
Figure 52 Colony Stimulating Factors Protein Type Segment Dominates the Asia PEGylated Proteins Market
Figure 53 Cancer, the Largest Application Segment in Asia
Figure 54 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the Asia Market
Figure 55 RoW: PEGylated Proteins Market Snapshot (2016)
Figure 56 Consumables, the Largest Product Segment in RoW
Figure 57 Colony Stimulating Factors Protein Type Segment Dominates the RoW PEGylated Proteins Market
Figure 58 Cancer Treatment, the Largest Application Segment in RoW
Figure 59 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the RoW Market
Figure 60 Key Developments in the PEGylated Proteins Market, 2013–2016
Figure 61 PEGylated Proteins Market Share Analysis, By Key Player, 2016
Figure 62 Financial Performances of the Leading Market Players
Figure 63 Company Snapshot: Merck Millipore
Figure 64 Thermo Fisher Scientific: Company Snapshot
Figure 65 Company Snapshot: NOF American Corporation (A Subsidiary of NOF Corporation)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Biomatrik, Inc.
  • Celares GmbH
  • Creative Pegworks
  • Iris Biotech GmbH
  • Jenkem Technology
  • Laysan Bio, Inc.
  • MORE

The global PEGylated proteins market is expected to USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016, at a CAGR of 10.5% between 2016 and 2021. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.

The report provides a granular understanding of the market. This report segments the global market on the basis of product, protein type, application, end-user and geography. The product segments included in this report are consumables and services. The consumables segment is further segmented into PEGylation reagents, and PEGylation kits. The consumables segment accounts for the largest share of the global market in 2016 owing to the increasing adoption of kit-based PEGylation products.

The protein type segment includes colony stimulating factors, interferons, erythropoietin, mAbs, and recombinant factor VIII. The colony stimulating factors segment is expected to grow at the highest rate among the protein type segments, owing to the increasing incidence of cancer across the globe and also to enhance the chemotherapy process. The application segment is segmented into cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, and gastrointestinal disorders. The end-user segments included in this report are pharmaceutical & biotechnology companies, CROs, and academic research institutes.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). The report maps each product, protein type, application and end-user segment in 6 geographic and regional segments. Geographic analysis reveals that North America accounted for the largest share of the global PEGylated proteins market in 2016. Growth in this market can be attributed to the increased adoption of biologics drugs such as monoclonal antibodies, erythropoietin and interferon for the treatment of chronic diseases; increasing government funding and grants for research activities, and increasing R&D spending for drug discovery at early stages. Similarly Asia is estimated to be the fastest growing market of the global market in 2016. The wide applications of PEGylated proteins in treating cancer, blood disorder, chronic and autoimmune disease are expected to drive the demand for market in this region.

The major players in this market include Merck Millipore (U.S.), Thermo Fisher Scientific, Inc. (U.S.), NOF Corporation (Japan), JenKem Technology USA, Inc. (U.S.), Creative PEGworks (U.S),  Celares GmbH (Germany), Quanta BioDesign, Ltd. (U.S.), Biomatrik, Inc, (China), Iris Biotech GmbH (Germany), Laysan Bio, Ltd. (U.S.).

Note: Product cover images may vary from those shown
5 of 5
  • Biomatrik, Inc.
  • Celares GmbH
  • Creative Pegworks
  • Iris Biotech GmbH
  • Jenkem Technology
  • Laysan Bio, Inc.
  • Merck Millipore
  • NOF American Corporation (A Subsidiary of NOF Corporation)
  • Quanta Biodesign, Ltd
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll